Literature DB >> 29956219

Authors' Response to Silverman and Colleagues' Comment on "Review of Case Narratives from Fatal Overdoses Associated with Injectable Naltrexone for Opioid Dependence".

Nabarun Dasgupta1, Roxanne Saucier2, Daniel Wolfe2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29956219     DOI： 10.1007/s40264-018-0692-9

Source DB:  PubMed          Journal:  Drug Saf        ISSN： 0114-5916            Impact factor:   5.606


× No keyword cloud information.
  5 in total

1.  CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials.

Authors:  David Moher; Sally Hopewell; Kenneth F Schulz; Victor Montori; Peter C Gøtzsche; P J Devereaux; Diana Elbourne; Matthias Egger; Douglas G Altman
Journal:  BMJ       Date:  2010-03-23

2.  Extended-release naltrexone (XR-NTX) for opioid use disorder in clinical practice: Vivitrol's Cost and Treatment Outcomes Registry.

Authors:  Andrew J Saxon; Sarah C Akerman; Chih-Chin Liu; Maria A Sullivan; Bernard L Silverman; Frank J Vocci
Journal:  Addiction       Date:  2018-04-01       Impact factor: 6.526

3.  Fatal and non-fatal opioid overdose in opioid dependent patients treated with methadone, buprenorphine or implant naltrexone.

Authors:  Erin Kelty; Gary Hulse
Journal:  Int J Drug Policy       Date:  2017-06-10

4.  Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.

Authors:  Joshua D Lee; Edward V Nunes; Patricia Novo; Ken Bachrach; Genie L Bailey; Snehal Bhatt; Sarah Farkas; Marc Fishman; Phoebe Gauthier; Candace C Hodgkins; Jacquie King; Robert Lindblad; David Liu; Abigail G Matthews; Jeanine May; K Michelle Peavy; Stephen Ross; Dagmar Salazar; Paul Schkolnik; Dikla Shmueli-Blumberg; Don Stablein; Geetha Subramaniam; John Rotrosen
Journal:  Lancet       Date:  2017-11-14       Impact factor: 79.321

5.  Comment on "Review of Case Narratives from Fatal Overdoses Associated with Injectable Naltrexone for Opioid Dependence".

Authors:  Bernard Silverman; Gary Bloomgren; Priya Jain; Kimberley Marcopul; Alexandra Silveira; James Fratantonio; Maria Sullivan; Sarah Akerman
Journal:  Drug Saf       Date:  2018-10       Impact factor: 5.606
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.